ENDOSCOPIC REMOVAL OF PAPILLARY TUMORS OF UPPER URINARY TRACT


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To assess the results of organ-sparing endoscopic treatment of patients with tumors of the upper urinary tract (UUT). Materials and methods . Twenty four patients underwent percutaneous and ureteropyeloscopic interventions for tumors of the upper urinary tract and were followed up at the Urology Clinic, I.M. Sechenov First MSMU. Retrograde removal of benign tumors of the renal pelvis and ureter (tumors sized from 5 to 35 mm), percutaneous removal of papillary carcinoma of renal pelvis of a solitary kidney, percutaneous removal of papillary carcinoma of renal pelvis of only one functioning kidney and percutaneous removal of papillary carcinoma of the lower calyx of the L-shaped kidney were performed in 21, 1, 1 and 1 patients, respectively. The patients had stage T1 papillary cancer of the upper urinary tract. There were 7 (29.2%) men and 17 (70.8%) women with mean age 64±5 years. Electroresection/ vaporization was carried out in 18 patients, and 6 patients were treated using Holmium laser. Results. None of the endoscopic procedures required conversion to open surgery or a more extended surgical operation. There were no recurrences or impaired UUT urinary flow in patients with benign UUT tumors at different points of follow-up. In 3 cases of malignant UUT tumors no recurrences occurred during 12-20 months follow-up. Conclusion and discussion. Nephroureterectomy with resection of the urinary bladder is the standard radical treatment of patients with tumors of the UUT. Technological advances in endoscopic and percutaneous surgery for UUT have allowed for organ-sparing procedures in patients with neoplasms of pelvicalyceal system and ureter. The absolute indications for such organ-sparing operations now include solitary kidney or only one functioning kidney and chronic renal failure. Endoscopic resection of the tumor and renal pelvic wall within healthy tissue, including by holmium laser, with tumor stage not exceeding T1 and followed by trans-fistula chemotherapy can be regarded as an effective treatment for patients with tumors of pelvicalyceal system.

Full Text

Restricted Access

About the authors

G. N Akopyan

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: docgagik@mail.ru

Yu. G Alyaev

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: ugalyaev@mail.ru

A. Z Vinarov

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: avinarov@mail.ru

L. M Rapoport

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: leonidrapoport@yandex.ru

M. A Gazimiev

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: gazimiev@yandex.ru

D. G Tsarichenko

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: tsarichenkodg@yandex.ru

E. V Shpot

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: shpot@inbox.ru

N. I Sorokin

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: nisorokin@mail.ru

A. M Dymov

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: alimdv@mail.ru
Clinic of Urology

A. M Pshikhachev

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: pshich@yandex.ru

V. Yu Lekarev

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: lekarev_bat@mail.ru

G. S Akopyan

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU

Email: g.s.akopyan@gmail.com

References

  1. Oosterlinck W., Solsona E., van der Meijden A.P. et al. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol. 2004;46(2):147-154.
  2. Babjuk M., Oosterlinck W., Sylvester R. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54(2):303-314.
  3. Stewart G.D., Bariol S.V., Grigor K.M. et al. A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int 2005;95(6):791-793.
  4. Olgac S, Mazumdar M, Dalbagni G et al. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol. 2004;28(12):1545-1552.
  5. Perez-Montiel D, Wakely P.E, Hes O. et al. High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants. Mod Pathol 2006;19(4):494-503.
  6. Hall M.C., Womack S., Sagalowsky A.I. et al. Prognostic factors, recurrence and survival in transitional cell carcinoma of upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52:594-601.
  7. Komyakov B.K., Idrisov Sh.N., Novikov A.I. i dr. Treatment of epithelial tumors of the upper urinary tracts. Urologiia. 2004;4:12-16. Russian (Комяков Б.К., Идрисов Ш.Н., Новиков А.И. и др. Оперативное лечение эпителиальных опухолей верхних моче- выводящих путей. Урология. 2004;4:12-16).
  8. Oosterlink W., Solsona E., Van der Meijden A.P. et al. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol. 2004;46:147-154.
  9. Argyropoulos A.N., Tolley D.A. Upper urinary tract transitional cell carcinoma: current treatment overview of minimally invasive approach. BJU Int. 2007;99:982-987.
  10. Zigeuner R., Pummer K. Urothelial carcinoma of the upper urinary tract: Surgical approach and prognostic factors. Eur Urol. 2008;53:720-731.
  11. Лопаткин Н.А., Мартов А.Г., Ергаков Д.В. Эндоскопические методы диагностики и лечения папиллярных опухолей верхних мочевыводящих путей. Урология. 2001;36:46-51
  12. Shalhav A.L., Portis A.J., Mc Dougall E.M. et al. Laparoscopic nephroureterectomy. A new standard for the surgical management of upper tract transitional cell cancer. Urol Clin North Am. 2000;27:761-773.
  13. Simone G., Papalia R., Guaglianone S., Ferriero M. et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomized prospective study. Eur Urol. 2009;56:520-526.
  14. Roupret M., Traxer O., Tligui M. et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol. 2007;51:709-714.
  15. Irwin B.H., Berger A.K., Brandina R. et al. Complex percutaneous resections of upper tract urothelial carcinoma. J Endourol. 2010;24:367-370.
  16. Zigeuner R., Pummer K. Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. Eur Urol. 2008;53(4):720-731.
  17. Brown G.A., Busby J.E., Wood C.G. et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 2006;98(6):1176-1180.
  18. Bagley D.H., Grasso M. 3rd. Ureteroscopic laser treatment of upper urinary tract neoplasms. World J Urol. 2010;28(2):143-149.
  19. Rouprêt M., Wallerand H., Traxer O. et al. Checkup and management of upper urinary tract tumours in 2010: An update from the committee of cancer from the French National Association of Urology. Prog Urol. 2010;20(4):260-271.
  20. Goodman T.M. Ureteroscopy with rigid instruments in the management of distal ureteral disease. J Urol. 1984;132:250-253.
  21. Smith A.K., Matin S.F., Jarrett T.W. Wein: Campbell-Walsh Urology, 11th ed., Chapter 58/Urothelial Tumors of the Upper Urinary Tract and Ureter. Elsevier 2013.
  22. Tomera K.M., Leary F.J., Kinke H. Pyeloscopy in urothelial tumors. J Urol. 1982;127:1088-1089.
  23. Goel M.C., Mahendra V., Roperts J.G. Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol. 2003;169:925-929.
  24. Clark P.E., Streem S.B., Geisinger M.A. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol. 1999;161:772-776.
  25. Fang, D. et al. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int. 2013; 91:291.
  26. Rastinehad A.R., Ost M.C., Vander Brink B.A. et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: Is there an oncologic benefit with adjuvant bacillus CalmetteGuerin therapy? Urology. 2009;73:27-31.
  27. Terakawa T., Miyake H., Muramaki M. et al. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology 2008 Jan;71(1):123-127.
  28. Raman J.D., Ng C.K., Boorjian S.A. et al. Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int 2005;96(7):1031-1035.
  29. Azémar M.D., Comperat E., Richard F., Cussenot O., Rouprêt M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillance. Urol Oncol.2011; 29(2):130-136.
  30. Cornu J.N., Rouprêt M., Carpentier X., Geavlete B., de Medina S.G., Cussenot O., Traxer O. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol. 2010;28:151.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies